Detection of IDH1 mutation in the plasma of patients with glioma
Authors:
- Jaime Gállego Pérez-LarrayaJPJaime Gállego Pérez-Larraya
- Marta RossettoMRMarta Rossetto
- Marianne LabussièreMLMarianne Labussière
- Pietro CiccarinoPCPietro Ciccarino
- Yannick MarieYMYannick Marie
- Jean-Yves DelattreJDJean-Yves Delattre
- Marc SansonMSMarc Sanson
- 16 October 2012
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 79 (16) , 1693-1698
Abstract
Objective: The IDH1R132H mutation is both a strong prognostic predictor and a diagnostic hallmark of gliomas and therefore has major clinical relevance. Here, we developed a new technique to detect the IDH1R132H mutation in the plasma of patients with glioma. Methods: Small-size DNA (150–250 base pairs) was extracted from the plasma of 31 controls and 80 patients with glioma with known IDH1R132H status and correlated with MRI data. The IDH1R132H mutation was detected by a combination of coamplification at lower denaturation temperature and digital PCR. Results: The small size DNA concentration was 1.2 ng/mL (range 0.1–6.6) in controls vs 1.2 ng/mL (range 0.1–50.3) in patients with glioma (p = not significant) and 0.9 ng/mL (0.0–3.0) in low-grade gliomas vs 1.5 ng/mL in high-grade gliomas (p < 0.01). The small size DNA concentration correlated with enhancing tumor volume (1.6 ng/mL [0.4–24.9] when 3 and 14.0 ng/mL [0.6–50.3] when ≥10 cm3). The IDH1R132H mutation was detected in 15 out of 25 plasma DNA mixtures (60%) from patients with mutated tumors and in none of the 14 patients with a nonmutated tumor. The sensitivity increased with enhancing tumor volume (3/9 in nonenhancing tumors, 6/10 for enhancing volume 3, and 6/6 for enhancing volume ≥10 cm3). Conclusion: With a specificity of 100% and a sensitivity related to the tumor volume and contrast enhancement, IDH1R132H identification has a valuable diagnostic accuracy in patients not amenable to biopsy.Keywords
This publication has 22 references indexed in Scilit:
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomasNature Medicine, 2012
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyJournal of Neuro-Oncology, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patientsJournal of Cancer Research and Clinical Oncology, 2010
- Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesNeuro-Oncology, 2010
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Methylated Tumor-Specific DNA as a Plasma Biomarker in Patients with GliomaCancer Investigation, 2006
- Biomarkers in Cancer Staging, Prognosis and Treatment SelectionNature Reviews Cancer, 2005
- Quantification of Free Circulating DNA As a Diagnostic Marker in Lung CancerJournal of Clinical Oncology, 2003